Clinical trials sponsored by Fudan University

Phase breakdown

Conditions studied

Recruiting trials led by Fudan University

• A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
  NCT05862064 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
  NCT06889610 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer
  NCT07653893 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
  NCT07604909 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Prospective Cohort Study on the Serum Kisspeptin Levels Throughout Pregnancy in PCOS
  NCT06545994 · Phase: Not specified · Ages: 18 Years to 40 Years · Sex: Female · 1 location
• A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal Metastases
  NCT06903325 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
  NCT06166147 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer
  NCT07562490 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
  NCT06992882 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• A Real World Study of Sacituzumab Govitecan
  NCT06966141 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
  NCT05969171 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
  NCT05999149 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 2 locations
• A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
  NCT06749015 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
  NCT06561555 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
  NCT05954429 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• AI-Enhanced Imaging in Population Breast Cancer Screening
  NCT07411443 · Phase: Not applicable (e.g. observational or device study) · Ages: 35 Years to 69 Years · Sex: Female · 1 location
• AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial
  NCT06642948 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female) · 1 location
• AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
  NCT06604689 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)
  NCT07544784 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
  NCT06475326 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
  NCT05861271 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Air Purifier Use and Respiratory Health in COPD Patients
  NCT07505602 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 80 Years · Sex: All (male and female) · 1 location
• All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial
  NCT06636981 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
  NCT07117630 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
  NCT06331169 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
  NCT06911528 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 1 location
• Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
  NCT07528716 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer
  NCT06684418 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Association Between Screening Behaviors and Lung Cancer Spectrum
  NCT07626177 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
  NCT06561620 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
  NCT06793332 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
  NCT07019363 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
  NCT06218810 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase
  NCT07555678 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
  NCT06341621 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
  NCT05954078 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer
  NCT05904665 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
  NCT06095141 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Combination of TURP and Standard Systemic Therapy for MPCa
  NCT06655259 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR
  NCT07371273 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
  NCT07398937 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
  NCT04687631 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis
  NCT06501378 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
  NCT07070700 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
  NCT05057052 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Digital Mind-Body Therapy for Neoadjuvant Breast Cancer
  NCT07541664 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 1 location
• EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
  NCT05883852 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)
  NCT03786003 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
  NCT04790305 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 34 locations
• Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal Cancer
  NCT06934018 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Effectiveness of Gut Microbiota-targeted Diatery Intervention Among Older People Living With HIV
  NCT06560840 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
  NCT05891093 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 15 locations
• Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
  NCT05954442 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
  NCT06440902 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
  NCT06427239 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
  NCT06547736 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• FUSCC Refractory TNBC Platform Study (FUTURE2.0)
  NCT05749588 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
  NCT05760378 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
  NCT06313970 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
  NCT07705438 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity
  NCT07586215 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• HPV Genotype Attribution and Disease Burden of Anal Cancer in China
  NCT06670495 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• HTA of NIVATS Based on RWE
  NCT06574295 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer
  NCT03856372 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: Female · 3 locations
• Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery
  NCT04025164 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: Female · 5 locations
• Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
  NCT06230055 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
  NCT06763029 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Ivonescimab in the Treatment of Multiple Advanced Tumors
  NCT06683846 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer
  NCT05939063 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Lymph Node Pathologic Grading Strategy
  NCT06745830 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Efficacy
  NCT07574749 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Multicentric Database for KRAS Mutant Pancreatic Cancer
  NCT07557849 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas
  NCT07183280 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Neoadjuvant SNF Precision Therapy Phase III
  NCT06913777 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
  NCT06516289 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
  NCT06369181 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Novel Therapy Target in Metastatic Prostate Cancer
  NCT05577689 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · 1 location
• ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
  NCT06775743 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery
  NCT07762885 · Phase: Phase 3 · Ages: 40 Years and older · Sex: Female · 1 location
• Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT
  NCT07557654 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
  NCT05759546 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
  NCT06359275 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction
  NCT05512286 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 6 locations
• Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
  NCT06965231 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
  NCT06841159 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
  NCT07134153 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer
  NCT07154316 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
  NCT06521866 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
  NCT07003022 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
  NCT05847855 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
  NCT06649331 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Postoperative Effects of Different Enterostomy Approaches
  NCT05853094 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
  NCT05806060 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC
  NCT07290153 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: Female · 3 locations
• QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
  NCT06786026 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
  NCT07445022 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer
  NCT06250972 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer
  NCT07562659 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer
  NCT07562711 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location

Showing 100 of 136 recruiting trials.

Common questions

How many trials is Fudan University recruiting for?

Fudan University is the lead sponsor of 136 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.